Poor agreement between interferon-gamma release assays and the tuberculin skin test among HIV-infected individuals in the country of Georgia

BMC Infectious Diseases

Volumn 13, Issue 1, 2013, Pages

  Chkhartishvili, Nikoloz ^a   Kempker, Russell R ^b   Dvali, Natia ^a   Abashidze, Lela ^a   Sharavdze, Lali ^a,c   Gabunia, Pati ^a   Blumberg, Henry M ^b,d,e   del Rio, Carlos ^b,d,e   Tsertsvadze, Tengiz ^a,c  

^a Infectious Diseases AIDS and Clinical Immunology Research Center   (Georgia)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c TBILISI STATE UNIVERSITY   (Georgia)

^d EMORY UNIVERSITY   (United States)

^e EMORY UNIVERSITY   (United States)

Author keywords

Eastern Europe; Interferon gamma; Latent tuberculosis infection; Screening; TST

Indexed keywords

ANTIRETROVIRUS AGENT; BCG VACCINE;

ADULT; ARTICLE; BLOOD SAMPLING; CD4 LYMPHOCYTE COUNT; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DETENTION; DIAGNOSTIC ACCURACY; DIAGNOSTIC KIT; DIAGNOSTIC TEST ACCURACY STUDY; DRUG ABUSE; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; GEORGIA (REPUBLIC); HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; INTERFERON GAMMA RELEASE ASSAY; INTERMETHOD COMPARISON; LATENT TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; MORBIDITY; QUESTIONNAIRE; RISK FACTOR; SEX DIFFERENCE; SKIN INDURATION; TUBERCULIN TEST; TUBERCULOSIS; MICROBIOLOGY; PROCEDURES; REPRODUCIBILITY; STANDARDS; VIROLOGY;

ADULT; CD4 LYMPHOCYTE COUNT; FEMALE; GEORGIA (REPUBLIC); HIV INFECTIONS; HUMANS; INTERFERON-GAMMA RELEASE TESTS; LATENT TUBERCULOSIS; MALE; REPRODUCIBILITY OF RESULTS; RISK FACTORS; TUBERCULIN TEST;

EID: 84886731297     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/1471-2334-13-513     Document Type: Article

References (38)

1. Selwyn P, Hartel D, Lewis V, Schoenbaum E, Vermund S, Klein R, Walker A, Friedland G. A prospective study of the risk of tuberculosis among intravenous drug users with human immunodeficiency virus infection. N Engl J Med 1989, 320:545-550. 10.1056/NEJM198903023200901, 2915665.
2. Allen S, Batungwanayo J, Kerlikowske K, Lifson A, Wolf W, Granich R, Taelman H, Van de Perre P, Serufilira A, Bogaerts J. Two-year incidence of tuberculosis in cohorts of HIV-infected and uninfected urban Rwandan women. Am Rev Respir Dis 1992, 146:1439-1444. 10.1164/ajrccm/146.6.1439, 1456559.
3. Taylor Z, Nolan CM, Blumberg HM. Controlling tuberculosis in the United States: recommendations from the American thoracic society, CDC, and the infectious diseases society of America. MMWR Recomm Rep 2005, 54:1-81.
4. World Health Organization Guidelines for Intensified Tuberculosis Case-Finding and Isoniazid Preventive Therapy for People Living with HIV in Resource-Constrained Settings 2011, Geneva: World Health Organization, World Health Organization.
5. Whalen CC. Diagnosis of latent tuberculosis infection: measure for measure. JAMA 2005, 293:2785-2787. 10.1001/jama.293.22.2785, 15941809.
6. Pai M, Zwerling A, Menzies D. Systematic review: T-cell-based assays for the diagnosis of latent tuberculosis infection: an update. Ann Intern Med 2008, 149:177-184. 10.7326/0003-4819-149-3-200808050-00241, 2951987, 18593687.
7. Cattamanchi A, Smith R, Steingart KR, Metcalfe JZ, Date A, Coleman C, Marston BJ, Huang L, Hopewell PC, Pai M. Interferon-gamma release assays for the diagnosis of latent tuberculosis infection in HIV-infected individuals: a systematic review and meta-analysis. J Acquir Immune Defic Syndr 2011, 56:230-238. 10.1097/QAI.0b013e31820b07ab, 3383328, 21239993.
8. WHO Regional Office for Europe European Health for All Database (HFA-DB): Tuberculosis Incidence 2012, Copenhagen: WHO Regional Office for Europe, http://data.euro.who.int/hfadb/, WHO Regional Office for Europe.
9. UNAIDS Global Report: UNAIDS Report on the Global AIDS Epidemic 2010 2010, Geneva: UNAIDS, UNAIDS.
10. Garfein RS, Lozada R, Liu L, Laniado-Laborin R, Rodwell TC, Deiss R, Alvelais J, Catanzaro A, Chiles PG, Strathdee SA. High prevalence of latent tuberculosis infection among injection drug users in Tijuana, Mexico. Int J Tuberc Lung Dis 2009, 13:626-632. 2744313, 19383197.
11. Martin V, de Garcia Olalla P, Orcau A, Cayla JA. Factors associated with tuberculosis as an AIDS-defining disease in an immigration setting. J Epidemiol 2011, 21:108-113. 10.2188/jea.JE20100072, 21325728.
12. Menzies D, Baussano I, Williams BG, Nunn P, Beggiato M, Fedeli U, Scano F. Tuberculosis incidence in prisons: a systematic review. PLoS Med 2010, 7:e1000381. 10.1371/journal.pmed.1000381, 3006353, 21203587.
13. Tsertsvadze T, Chkhartishvili N, Gamkrelidze A, Rukhadze N, Bolokadze N, Gabunia P, Sharvadze L. Analysis of Causes of Death among HIV-Infected Persons in Georgia, 1989-2009 2010, Vienna: XVIII International AIDS Conference, Abstract no. TUPE0225.
14. Skinner HA. The drug abuse screening test. Addict Behav 1982, 7:363-371. 10.1016/0306-4603(82)90005-3, 7183189.
15. Babor TF, Higgins-Biddle JC, Saunders JB, Monteiro MG. AUDIT: The Alcohol Use Disorders Identification Test: Guidelines for Use in Primary Health Care 2001, Geneva: World Health Organization, 2.
16. Centers for Disease Control and Prevention Targeted tuberculin testing and treatment of latent tuberculosis infection: American thoracic society. MMWR Recomm Rep 2000, 49:1-51. Centers for Disease Control and Prevention.
17. Mazurek GH, Jereb J, Vernon A, LoBue P, Goldberg S, Castro K. Updated guidelines for using interferon gamma release assays to detect mycobacterium tuberculosis infection - United States, 2010. MMWR Recomm Rep 2010, 59:1-25.
18. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)-a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform 2009, 42:377-381. 10.1016/j.jbi.2008.08.010, 2700030, 18929686.
19. Kraemer HC. Measurement of reliability for categorical data in medical research. Stat Methods Med Res 1992, 1:183-199. 10.1177/096228029200100204, 1341657.
20. Bursac Z, Gauss CH, Williams DK, Hosmer D. Purposeful selection of variables in logistic regression. Source Code Biol Med 2008, 3:17. 10.1186/1751-0473-3-17, 2633005, 19087314.
21. Leidl L, Mayanja-Kizza H, Sotgiu G, Baseke J, Ernst M, Hirsch C, Goletti D, Toossi Z, Lange C. Relationship of immunodiagnostic assays for tuberculosis and numbers of circulating CD4+ T-cells in HIV infection. Eur Respir J 2009, 35:619-626.
22. Talati NJ, Seybold U, Humphrey B, Aina A, Tapia J, Weinfurter P, Albalak R, Blumberg HM. Poor concordance between interferon-gamma release assays and tuberculin skin tests in diagnosis of latent tuberculosis infection among HIV-infected individuals. BMC Infect Dis 2009, 9:15. 10.1186/1471-2334-9-15, 2649136, 19208218.
23. Stephan C, Wolf T, Goetsch U, Bellinger O, Nisius G, Oremek G, Rakus Z, Gottschalk R, Stark S, Brodt H-R, Staszewski S. Comparing QuantiFERON-tuberculosis gold, T-SPOT tuberculosis and tuberculin skin test in HIV-infected individuals from a low prevalence tuberculosis country. AIDS 2008, 22:2471-2479. 10.1097/QAD.0b013e3283188415, 19005270.
24. Mandalakas AM, Hesseling AC, Chegou NN, Kirchner HL, Zhu X, Marais BJ, Black GF, Beyers N, Walzl G. High level of discordant IGRA results in HIV-infected adults and children. Int J Tuberc Lung Dis 2008, 12:417-423.
25. Talati NJ, Gonzalez-Diaz E, Mutemba C, Wendt J, Kilembe W, Mwananyanda L, Chomba E, Allen S, Del Rio C, Blumberg HM. Diagnosis of latent tuberculosis infection among HIV discordant partners using interferon gamma release assays. BMC Infect Dis 2011, 11:264. 10.1186/1471-2334-11-264, 3198954, 21962029.
26. Oni T, Gideon HP, Bangani N, Tsekela R, Seldon R, Wood K, Wilkinson KA, Goliath RT, Ottenhoff TH, Wilkinson RJ. Risk factors associated with indeterminate interferon gamma responses in the assessment of latent tuberculosis infection in a high incidence environment. Clin Vaccine Immunol 2012, 19:1243-1247. 10.1128/CVI.00166-12, 3416070, 22718129.
27. Weinfurter P, Blumberg HM, Goldbaum G, Royce R, Pang J, Tapia J, Bethel J, Mazurek GH, Toney S, Albalak R. Predictors of discordant tuberculin skin test and QuantiFERON®-TB Gold In-Tube results in various high-risk groups. Int J Tuberc Lung Dis 2011, 15:1056-1061. 10.5588/ijtld.10.0650, 21740668.
28. Balcells ME, Pérez CM, Chanqueo L, Lasso M, Villanueva M, Espinoza M, Villarroel L, García P. A comparative study of two different methods for the detection of latent tuberculosis in HIV-positive individuals in Chile. Int J Infect Dis 2008, 12:645-652. 10.1016/j.ijid.2008.03.005, 18534887.
29. Gray J, Reves R, Johnson S, Belknap R. Identification of false-positive QuantiFERON-TB Gold In-Tube assays by repeat testing in HIV-infected patients at low risk for tuberculosis. Clin Infect Dis 2012, 54:e20-23. 10.1093/cid/cir792, 22057704.
30. Getahun H, Gunneberg C, Sculier D, Verster A, Raviglione M. Tuberculosis and HIV in people who inject drugs: evidence for action for tuberculosis, HIV, prison and harm reduction services. Curr Opin HIV AIDS 2012, 7:345-353. 10.1097/COH.0b013e328354bd44, 22678489.
31. Clark SA, Martin SL, Pozniak A, Steel A, Ward B, Dunning J, Henderson DC, Nelson M, Gazzard B, Kelleher P. Tuberculosis antigen-specific immune responses can be detected using enzyme-linked immunospot technology in human immunodeficiency virus (HIV)-1 patients with advanced disease. Clin Exp Immunol 2007, 150:238-244. 10.1111/j.1365-2249.2007.03477.x, 2219352, 17672869.
32. Aichelburg MC, Rieger A, Breitenecker F, Pfistershammer K, Tittes J, Eltz S, Aichelburg AC, Stingl G, Makristathis A, Kohrgruber N. Detection and prediction of active tuberculosis disease by a whole-blood interferon-gamma release assay in HIV-1-infected individuals. Clin Infect Dis 2009, 48:954-962. 10.1086/597351, 19245343.
33. Elliott JH, Vohith K, Saramony S, Savuth C, Dara C, Sarim C, Huffam S, Oelrichs R, Sophea P, Saphonn V, et al. Immunopathogenesis and diagnosis of tuberculosis and tuberculosis-associated immune reconstitution inflammatory syndrome during early antiretroviral therapy. J Infect Dis 2009, 200:1736-1745. 10.1086/644784, 19874177.
34. Denkinger CM, Dheda K, Pai M. Guidelines on interferon-gamma release assays for tuberculosis infection: concordance, discordance or confusion?. Clin Microbiol Infect 2011, 17:806-814. 10.1111/j.1469-0691.2011.03555.x, 21682801.
35. World Health Organization. Regional Office for Europe Patient Evaluation and Antiretroviral Treatment for Adults and Adolescents: Clinical Protocol for the WHO European Region 2012, Copenhagen: WHO Regional Office for Europe, World Health Organization. Regional Office for Europe.
36. Canadian Tuberculosis Committee Recommendations on interferon gamma release assays for the diagnosis of latent tuberculosis infection - 2010 Update. Can Commun Dis Rep 2010, 36:1-22. Canadian Tuberculosis Committee.
37. LoBue PA, Castro KG. Is it time to replace the tuberculin skin test with a blood test?. JAMA 2012, 308:241-242. 10.1001/jama.2012.7511, 22797639.
38. de Perio MA, Tsevat J, Roselle GA, Kralovic SM, Eckman MH. Cost-effectiveness of interferon gamma release assays vs tuberculin skin tests in health care workers. Arch Intern Med 2009, 169:179-187. 10.1001/archinternmed.2008.524, 19171815.